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OBJECTIVE — To assess the effect of a 4-week adjunctive therapy of exenatide (EXE) (5–10 g
b.i.d.)orsitagliptin(SITA)(100mgoncedaily)inresponsetoastandardizedbreakfastmealchallenge
in 48 men or women with type 2 diabetes receiving insulin glargine (GLAR)  metformin (MET).
RESEARCH DESIGN AND METHODS — This was a single-center, randomized, open-
label, active comparator–controlled study with a three-arm parallel group design, consisting of:
screening, 4- to 8-week run-in period, 4-week treatment period, and follow-up. In all three
groups, the GLAR dose was titrated according to an algorithm (fasting blood glucose 100
mg/dl).
RESULTS — The unadjusted 6-h postprandial blood glucose excursion of both GLAR 
METEXEandGLARMETSITAwasstatisticallysigniﬁcantlysmallerthanthatofGLAR
MET (606  104 vs. 612  133 vs. 728  132 mg/dl/h; P  0.0036 and 0.0008). A1C
signiﬁcantly decreased in all three groups (P  0.0001), with the greatest reduction of 1.9 
0.7 under GLAR  MET  EXE (GLAR  MET  SITA 1.5  0.7; GLAR  MET 1.2 
0.5%-points; GLAR  MET  EXE vs. GLAR  MET P  0.0154). The American Diabetes
AssociationA1Ctargetof7.0%wasreachedby80.0,87.5,and62.5%ofsubjects,respectively.
GLAR  MET  EXE had the highest number (47) of adverse events, mostly gastrointestinal
(56%) with one dropout. GLAR  MET or GLAR  MET  SITA only had 10 and 12 adverse
events, respectively, and no dropouts. Hypoglycemia (blood glucose 50 mg/dl) rates were low
and comparable among groups. Weight decreased with GLAR  MET  EXE (0.9  1.7 kg;
P  0.0396) and increased slightly with GLAR  MET (0.4  1.5 kg; NS; GLAR  MET  EXE
vs. GLAR  MET P  0.0377).
CONCLUSIONS — EXE or SITA added to GLAR  MET further substantially reduced
postprandialbloodglucoseexcursions.Longer-termstudiesinalargerpopulationarewarranted
to conﬁrm these ﬁndings.
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T
he UK Prospective Diabetes Study
(UKPDS)demonstratedthatgoodgly-
cemic control in type 2 diabetes is as-
sociated with a reduced risk of diabetes
complications (1). After lifestyle modiﬁca-
tions(dietandexercise)andoralhypogly-
cemicagents(OHAs)theadditionofbasal
insulin to OHAs is common practice (2),
because this kind of regimen requires
only a single injection in most cases and
can improve glycemic control. Its use,
however, may not adequately control
postprandialhyperglycemiaormaybeas-
sociated with hypoglycemia and/or
weight gain (3,4). Because obesity is fre-
quently present in subjects with type 2
diabetes (5) and represents a factor con-
tributing to insulin resistance (5) and car-
diovascular risk (5), weight gain may be
particularly undesirable.
A signiﬁcant advance in basal insulin
therapy was the introduction of insulin
glargine,along-actinginsulinanalogwith
an extended duration of action of 24 h
without exhibiting a pronounced peak
(6,7). In subjects with type 2 diabetes,
insulin glargine was shown to confer gly-
cemic control at least equivalent to that of
NHPinsulinwithalowerincidenceofhy-
poglycemia (3,8,9). However, insulin
glargine still has the drawbacks of insulin
treatment such as weight gain (3,8,9) and
a lower effect on postprandial glucose ex-
cursions (8) than on fasting glucose
values.
Exenatide is the ﬁrst-in-class gluca-
gon-like peptide 1 (GLP-1) receptor ago-
nist (or incretin mimetic) approved in the
U.S. and Europe (10). Compared with
placebo, exenatide statistically reduced
A1C, whereas there was no difference in
A1C improvement between exenatide
and insulin glargine or biphasic insulin
aspart (11–14). However, postprandial
glycemia as well as weight was further re-
duced with exenatide compared with in-
sulin glargine or biphasic insulin, with a
similar risk of hypoglycemia (12,13).
Sitagliptin is an approved once-daily,
potent, and highly selective dipeptidyl
peptidase-4 (DPP-4) inhibitor (15).
When added to metformin, sitagliptin,
givenatadoseof100mgoncedailyover24
weeks, led to signiﬁcant reductions in A1C,
fasting, and 2-h postprandial plasma glu-
cose and was weight-neutral (16).
Withthisbackground,atherapycon-
trolling both fasting blood glucose (FBG)
and postprandial glucose excursions
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jectswithtype2diabetes(17–21).There-
fore, in the present study we investigated
the inﬂuence of a 4-week adjunctive ther-
apyofeitheraGLP-1receptoragonist(ex-
enatide) or a DPP-4 inhibitor (sitagliptin)
to titrated basal insulin (insulin glargine)
plus metformin versus the continuation
with titrated insulin glargine plus met-
formin alone as active comparator in sub-
jects with type 2 diabetes.
RESEARCH DESIGN AND
METHODS— Enrolled subjects were
men or women aged 35–70 years, with
type 2 diabetes for 6 months and 10
years, treated either with a stable dose of
metformin with or without sulfonylureas
or treated solely with a long- or interme-
diate-acting insulin formulation (insulin
glargine,insulindetemir,orNPHinsulin)
with or without a stable dose of met-
formin for at least 3 months. Inclusion
criteria included BMI between 21.0 and
39.9 kg/m
2 inclusive, A1C 7.0 and
10.0%, and stable antihypertensive or
lipid-lowering therapy for at least 3
months, if applicable. Subjects were ex-
cluded,iftheyhadahistoryorevidenceof
any other clinically relevant medical con-
ditions or had used a rapid-acting insulin
or a mixed insulin formulation or any
other oral antidiabetic agent except for
metformin or metformin plus sulfonyl-
urea during the previous 3 months. Exclu-
sion criteria further included abnormal
laboratory test results, in particular, ala-
nine aminotransferase and/or aspartate
aminotransferase 3 times the laborato-
ry’s upper limit of reference range or se-
rum creatinine 1.6 mg/dl for men and
1.4 mg/dl for women, uncontrolled hy-
pertension, anemia, recurrent hypoglyce-
mia, or any systemic or topical treatment
with drugs known to inﬂuence glucose
metabolism.
This single-center, randomized, open-
label, active comparator–controlled study
with a three-arm parallel group design was
performed between 9 January and 29 Sep-
tember 2008. It was conducted in accor-
dancewiththeprinciplesoftheDeclaration
of Helsinki (22) and approved by the local
ethics committee and regulatory authori-
ties. All subjects provided written informed
consent.
Study protocol and treatment
After a screening visit (visit 0) to assess a
subject’s eligibility for study participa-
tion, a 4- or 8-week run-in period, de-
pending on the subject’s preexisting
antidiabetictherapy,withinsulinglargine
at bedtime followed, starting at visit 1:4
weeks run-in for a subject who already
had an insulin pretreatment or 8 weeks
for a subject who had oral antidiabetes
treatment only (OHA). Preexisting treat-
ment with metformin was continued for
the entire study, whereas sulfonylurea
treatmentwasstoppedatthebeginningof
the run-in period. All subjects received
insulin glargine at bedtime, at a starting
dose of 10 units for those subjects new to
insulin. During the whole course of the
study each subject’s insulin glargine dose
was titrated to a FBG target of 5.6
mmol/l (100 mg/dl) using a predeﬁned
treatment algorithm which, with slight
modiﬁcations, corresponds to that used
by Riddle et al. (8) in the treat-to-target
trial for the introduction of insulin
glargine to oral antidiabetes drug–treated
patients with type 2 diabetes. During the
run-inperiodtelephonecontacts(twoper
week) and weekly outpatient visits (visits
2–4or2–4dforthe8-weekrun-in)atthe
study site were performed. At the end of
therun-inperiod,2daysbeforeallocation
to one of the three treatment arms, the
insulinglarginedosewasreducedby20%
to avoid hypoglycemia. At visit 5 (base-
line), subjects in an open-label fashion
were randomly assigned to either the ad-
ditionofexenatideorsitagliptintoinsulin
glargine plus metformin (GLAR 
MET  EXE or GLAR  MET  SITA,
respectively) or to the continuation of in-
sulin glargine plus metformin alone
(GLAR  MET) for 4 weeks. Exenatide
was to be administered subcutaneously at
adoseof5ginthemorningandevening
(b.i.d.) for 2 weeks followed by 10 g
b.i.d. for the second 2 weeks. Sitagliptin
was taken orally at a dose of 100 mg once
daily in the morning. During the 4-week-
treatment period, weekly visits (visits
6–8) at the study site plus twice weekly
telephonecontactswerecontinuedtofur-
ther titrate blood glucose to the FBG tar-
get of 5.6 mmol/l (100 mg/dl). The
4-week treatment period ended with a
24-hin-housevisit,duringwhichefﬁcacy
assessmentswereperformed(visit9).The
study was completed with a ﬁnal visit
(visit 10) 2–10 days after the in-house
stay.
During both the run-in and the treat-
ment period, subjects self-measured and
recorded their FBG (and any potential
voluntary preprandial and/or postpran-
dial blood glucose values) on a daily basis
using a commercial glucose meter (Accu-
Chek® Aviva; Roche Diagnostics, Mann-
heim, Germany). Once per week they
performed 7-point blood glucose proﬁles
atthefollowingtimes:beforeand2hafter
breakfast, lunch, and dinner and before
bedtime(11:00 P.M.).Allresultsandtimes
of self-measurements of blood glucose as
well as insulin doses were entered by the
subjects into a study diary. If at any time
during the study (except at screening and
the ﬁnal visit) self-measured FBG values
on 2 consecutive days of 13.3 mmol/l
(240 mg/dl) were conﬁrmed at the site
by means of a validated glucose oxidase
method (Super-GL glucose analyzer; Hi-
tado Diagnostic Systems, Mo ¨hnesee, Ger-
many), the subject had to be withdrawn
from the study. The same procedure ap-
pliedforhypoglycemicbloodglucoseval-
ues occurring at 2 consecutive days.
Hypoglycemia was classiﬁed as major if a
subject was not able to treat the episode
himselforherself,andasminorifthesub-
ject was able to treat the episode himself
or herself and blood glucose was 2.8
mmol/l (50 mg/dl) or if no blood glu-
cose value was available or if blood glu-
cose was 2.8 mmol/l (50 mg/dl) with
symptoms only.
In addition to a thorough review of
the subject’s blood glucose values in the
studydiaryandadjustmentsoftheinsulin
glargine dose, the following assessments
were performed at the weekly visits at the
study site: vital signs, i.e., blood pressure
and heart rate; adverse events and hypo-
glycemic episodes (at each visit); physical
examination and safety laboratory (at
screening, before random assignment at
visit 5 and at the ﬁnal visit); pregnancy
test for women of child-bearing potential
(at screening, at visits 5 and 9, and at the
ﬁnal visit); electrocardiogram (ECG) (at
screening and at the ﬁnal visit), FBG (at
screeningandatvisits5,7,and9[onboth
days of the 24-h in-house stay]); and fast-
ing lipid proﬁle (at visits 5 and 9). At visit
9, during the 24-h in-house stay the fol-
lowing was assessed on day 1: dosing of
either exenatide or sitagliptin 60 min be-
fore a standardized 618.2 kcal breakfast
consistingof99.4gcarbohydrates,11.9g
lipids, and 26.2 g protein, a 7-point 24-h
blood glucose proﬁle, postprandial blood
glucose excursions after the standardized
breakfast (16 blood glucose samples from
30 to 360 min). On day 2 of the in-
house stay, after completion of all assess-
ments including A1C, the subjects were
instructed on how to continue with their
prestudy antidiabetes medication and
were asked to measure at least FBG and
document these measurements as well as
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diary provided.
Study end points
The primary outcome measure was the
unadjusted 6-h postprandial blood glu-
cose excursion (AUC BG0–6h) after in-
gestion of the standardized breakfast,
assessed at the end of the 4-week treat-
ment period. Secondary end points in-
cluded the following: mean daily blood
glucose as assessed by means of the
7-point 24-h blood glucose proﬁle at the
end of the 4-week treatment period,
the subjects’ self-measurements of FBG
and the 7-point blood glucose proﬁles
throughout the run-in and the treatment
period, the percentage of subjects achiev-
ing American Diabetes Association treat-
mentgoals,i.e.,A1C7.0%,attheendof
the treatment period, fasting lipid proﬁle,
body weight, each as assessed at the end
of the treatment period, number and se-
verity of hypoglycemic episodes, and gen-
eral safety parameters (adverse events,
physicalexamination,vitalsigns,safetylab-
oratory parameters, and ECG recordings).
Statistical analysis
Asamplesizeof16subjectspertreatment
arm (in a total of 48 subjects) was esti-
mated to detect signiﬁcant differences be-
tween treatments (23). SAS (version 9.1;
SAS Institute, Cary, NC) was used to con-
duct all statistical analyses. ANCOVA
models, allowing the estimation of least
squares means with corresponding 95%
conﬁdence limits, were used on untrans-
formed	bodyweight,	lipids,and	A1C
and on natural logarithm–transformed
AUC BG(0–6h), and 7-point blood glu-
cose proﬁle, with baseline assessments as
confounders. ANCOVA models with re-
peated measures on the factor day were
applied to test for differences in logarithm-
transformed FBG and self-measured
7-pointbloodglucose.Forlog-transformed
data, the calculated 95% CIs were back-
transformed to derive the appropriate
conﬁdence limits for the geometric mean
ratios of the pairwise treatment compari-
sons. Paired t tests were used to test with-
in-groupchanges,andforbetween-group
comparisons unpaired t tests were ap-
plied. 

2 tests were used to compare the
frequency of subjects achieving ADA
treatmentgoals(A1C7.0%)andofsub-
jects achieving International Diabetes
Federation treatment goals (A1C 6.5%)
at the end of the treatment period. De-
scriptive statistics on demographics,
safety, and glycemic end points were pro-
vided for all randomly assigned subjects
who received at least one dose of investi-
gational medication. The areas under the
blood glucose curve, extending from the
meal intake to 6 h after ingestion, were
calculated using the trapezoid rule. 	
A1C was determined as the difference of
visit 9 A1C minus screening A1C. 	 body
weight as well as 	 lipid were calculated
as visit 9 values minus visit 5 values. The
statistical signiﬁcance level was set at P 
0.05. Data are means  SD if not other-
wise stated.
RESULTS
Subject disposition and clinical
characteristics
A total of 48 subjects with type 2 diabetes
(60.4% men, aged [mean  SD] 57  7
years, with BMI 31.7  3.4 kg/m
2, diabe-
tes duration 6  1 years, and A1C 8.1 
0.7%) were randomly assigned to three
arms: GLAR  MET  EXE (up to 10 g
b.i.d.; n  16), GLAR  MET  SITA
(100 mg q.d.; n  16), or continuation
withGLARMET(control;n16)for4
weeks (Fig. 1). Of the subjects, 47 com-
pleted the study according to the proto-
col. One subject in the GLAR  MET 
EXEgroupwaswithdrawnaftertheﬁrst2
weeks of the 4-week treatment period
(becauseofalossofappetitedeemedtobe
possibly related to the study treatment).
Baseline A1C was 7.9% in both the
GLAR  MET  SITA and GLAR  MET
groups, whereas it was slightly higher
(8.4%) in the GLAR  MET  EXE
group. This difference, however, was not
of statistical signiﬁcance. All subjects
were receiving MET at the study start; in
addition, 7 subjects had preexisting sul-
fonylurea therapy and 9 subjects had
been treated with insulin.
Primary and secondary end points
After4weeksoftreatmenttheAUCBG0–6h
values of both GLAR  MET  EXE and
GLAR  MET  SITA were signiﬁcantly
smaller(EXE17%reduction,P0.0036;
SITA 20% reduction, P  0.0008) than
that of GLAR  MET, whereas values for
the two combination treatments were not
signiﬁcantly different from each other
(P  0.5734) (Table 1, Fig. 2).
A1C signiﬁcantly declined in all three
groups (least squares means GLAR 
METEXE1.8,GLARMETSITA
1.5, and GLAR  MET 1.2; P 
0.0001 each) with GLAR  MET  EXE
leading to a signiﬁcantly higher A1C de-
crease than GLAR  MET (least squares
mean 0.6, P  0.0154). Metabolic con-
trol on average was excellent: the ADA
A1C target of 7% was achieved by 80%
of subjects in the GLAR  MET  EXE
group, 88% of subjects in the GLAR 
MET  SITA group, and 63% of subjects
in the GLAR  MET group.
With GLAR  MET  EXE and
GLAR  MET  SITA, the 7-point 24-h
blood glucose proﬁles after 4 weeks of
treatment were signiﬁcantly lower than
those under GLAR  MET. The weekly
self-measured 7-point blood glucose pro-
ﬁles were also lower during the treatment
period.
Self-measured daily FBG values
(mean of all measurements in treatment
period)werecomparableamongthethree
treatments after signiﬁcant decreases in
FBG had been reached already during the
run-in period. However, when FBG at
randomization (visit 5) was compared
with that at the end of the 4-week treat-
ment (visit 9), a signiﬁcant reduction was
observed for each of the combination
treatments (P  0.0018 for GLAR 
MET  EXE and P  0.0016 for GLAR 
MET  SITA), whereas this was not the
case for GLAR  MET (P  0.2084).
Both adjunctive therapies showed a
comparable lowering effect on serum
cholesterol (total and LDL). This effect
was not seen in the control group.
Body weight was stable with GLAR 
MET and GLAR  MET  SITA (0.4 
1.5 and 0.1  1.6 kg, respectively) and
slightly decreased with GLAR  MET 
EXE (0.9  1.7 kg), which was statisti-
cally signiﬁcant versus GLAR  MET
(P  0.0377).
Hypoglycemic episodes and general
safety
Overthe4-weektreatmentperiodnoma-
jorhypoglycemicepisodeoccurredinany
of the three groups. Thirteen subjects ex-
perienced in total 22 hypoglycemic epi-
sodes: 5 subjects in the GLAR  MET 
EXE group experienced 12 hypoglycemic
episodes (10.1 events per subject year), 2
of these were minor (1.7 events per sub-
ject year) and 10 were symptoms only
(GLAR  MET  SITA group: 2 subjects,
4 hypoglycemic episodes, 3.3 events per
subject year, 3 were minor  2.5 events
per subject year; GLAR  MET: 6 sub-
jects, 6 hypoglycemic episodes, 2 were
minor  1.6 events per subject year).
Two subjects in the GLAR  MET  EXE
grouphad4hypoglycemicepisodeseach.
There was no nocturnal hypoglycemia
(between 11:00 P.M. and 6:00 A.M.) in any
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glycemic episodes in the GLAR  MET 
EXE group occurred between 6:00 and
7:00 P.M., whereas all hypoglycemic epi-
sodes in the GLAR  MET group took
place between 10 A.M. and 2:30 P.M.
The insulin glargine dose did not de-
crease with EXE or SITA, whereas it in-
creased in the control group. Mean
insulin doses at randomization and at the
end of treatment were 40.3 IU (0.60 
0.25 IU/kg) and 41.1 IU (0.42  0.18
IU/kg) in the GLAR  MET  EXE group
(GLAR  MET  SITA: 33.4 IU [0.50 
0.20 IU/kg] and 35.0 IU [0.36  0.17
IU/kg]; GLAR  MET: 32.3 IU [0.50 
0.21 IU/kg] and 37.9 IU [0.42  0.20
IU/kg]), with a mean increase of 5.6 IU in
the GLAR group.
Ten of the 16 subjects (62.5%) in the
GLAR  MET  EXE group experienced
in total 47 adverse events, 56% being due
to gastrointestinal disorders and causing
1 dropout after 2 weeks (in the GLAR 
MET  SITA group 7 subjects had 12
adverse events and in the GLAR  MET
group 4 subjects had 10 adverse events;
gastrointestinal disorders were 19 and
16%, respectively). All gastrointestinal
adverseeventswereofmildormoderate
intensity. There was no serious adverse
event in any of the groups and only one
severe adverse event, not related to trial
Figure 1—Subject disposition. AE, adverse event; ALT, alanine aminotransferase; AST, aspartate transferase.
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No clinically relevant ﬁndings or
changes were seen in safety laboratory
tests, physical examination results, ECG
recordings, and vital sign measurements.
CONCLUSIONS — To our knowl-
edge this is the ﬁrst study investigating a
4-week adjunctive therapy of either a
GLP-1 analog or a DPP-4 inhibitor added
to titrated insulin glargine plus met-
formin, compared with insulin glargine
plusmetforminaloneactingasactivecon-
trol in subjects with type 2 diabetes. The
addition of exenatide or sitagliptin to in-
sulin glargine plus metformin led to sta-
tistically signiﬁcant improvements in
nearly all parameters of metabolic con-
trol: postprandial glucose excursions as
well as A1C, 7-point blood glucose
proﬁles, FBG, and lipids were all lower
with the combination therapy compar-
ed with the control therapy, which is in
line with previous data (17,19,20). Over-
all glycemic control in all groups was ex-
cellent, as shown by 60% of all patients
reaching the ADA A1C target of 7%.
Body weight decreased with exenatide
and was stable in the other two groups,
indicating that the weight-lowering
activity of GLP-1 receptor stimulation
(10,20) persists even with concomitant
insulin treatment. This is an important
novel ﬁnding. The incidence of hypogly-
cemic episodes (blood glucose 50 mg/
dl) was comparable among groups and in
the expected range for insulin-treated pa-
tients (24). Gastrointestinal side effects,
however, were more frequent with ex-
enatide, which is consistent with the ad-
verse event proﬁle seen during phase III
(10).
Several factors should be considered
when interpreting our results. First, the
number of patients (16 in each group) is
relativelysmall;thus,furtherstudiesboth
in a larger number of patients and of
longer duration are warranted. Second,
mean duration of type 2 diabetes in this
population was only 6  1 years, and
mean baseline A1C was 8.1  0.7%. Pa-
tientswithlongerdiseasedurationand/or
worse metabolic control might be less
likely to beneﬁt to the extent seen in the
study population, especially when the fo-
cusisonpostprandialbloodglucose(25).
For the present subject group, one could
alsoconcludethatitismorecost-effective
to just continue metformin plus basal in-
sulin glargine, because overall glucose
control at the end of the study has signif-
icantly improved in all three groups, with
a slightly further improvement only seen
for the addition of exenatide given to ti-
trated insulin glargine plus metformin.
Moreover, the present subjects might not
be the ones requiring the combination of
metformin with insulin and sitagliptin/
exenatide, because excellent glucose con-
trol is achieved with insulin and metformin
alone and would most likely also be
achievedwithmetforminplusanincretin.
Nevertheless, this study provides a proof
of concept. Besides, given the increasing
incidence of type 2 diabetes and obesity
(5), there is a need for further effective,
weight-focused, convenient, and safe
therapies including incretins (21). Future
research will be necessary to clarify
whether there are clinical beneﬁts in
choosing exenatide or sitagliptin versus
another commonly used agent to lower
postprandial blood glucose. Another lim-
itationofthestudywasastatisticallynon-
signiﬁcant, slight difference, however, in
baseline A1C values among the three
groups, which should be taken into ac-
count when the results are interpreted.
Furthermore, the duration of the study
wastooshorttoseethefulleffectonA1C.
The open-label design also represents a
certain limitation. A double-blind dou-
ble-dummy design, however, would have
put a lot of effort into the conduct of the
Table 1—Primary and secondary end points
Parameter Time point* GLARMETEXE GLARMETSITA GLARMET
n 15 16 16
AUCBG0–6 h (mg/dl/h) EOT 606  104† 612  133† 728  132
BG0–6 h (mg/dl)‡ EOT 97§ 96§ 116
Mean BG (mg/dl) EOT 97  17† 100  18† 121  19
FBG (mg/dl) Baseline 94 96 94
EOT 82 84 89
Mean from self-measured 7-point BG proﬁles (mg/dl) Baseline–EOT 109† 109† 118
Self-measured FBG (mg/dl) Baseline–EOT 93 93 96
A1C (%) Screen 8.39  0.98 7.89  0.48 7.91  0.57
EOT 6.53  0.59 6.41  0.50 6.73  0.42
Change 1.80† 1.49 1.23
A1C 7.0% (% patients) EOT 80¶ 88¶ 63
Changes in total cholesterol (mmol/l) Baseline–EOT 0.24  0.48§ 0.27  0.61§ 0.30  0.52
Changes in HDL cholesterol (mmol/l) Baseline–EOT 0.04  0.14 0.04  0.21 0.08  0.17
Changes in LDL cholesterol (mmol/l) Baseline–EOT 0.30  0.46† 0.28  0.42† 0.09  0.36
Changes in body weight (kg) Baseline–EOT 0.9  1.7† 0.1  1.6 0.4  1.5
Hypoglycemic episodes (events per subject year) Major — — —
BG 50 mg/dl 2 (1.68) 3 (2.45) 2 (1.62)
Symptoms only 10 1 4
Adverse events Total 47 (62.5) 12 (43.8) 10 (25.0)
Gastrointestinal disorders 28 (56.3) 4 (18.8) 1 (6.3)
DataaremeansSD,geometricmeans(leastsquaresmeans)forcomparisons,orn(%)unlessotherwiseindicated.AUCBG0–6h,areaunderthebloodglucosecurve
0–6hafterastandardbreakfast;BG,bloodglucose.*Screen,beforewashoutoforalagentsexceptformetforminandrun-inperiod;Baseline,beforerandomization;
EOT, end of treatment. †P  0.05 vs. GLAR. ‡Post hoc analysis (repeated-measures ANCOVA). §P  0.01 vs. GLAR. P  0.05 vs. Screen/Baseline; ¶P  0.05 (

2
test) vs. A1C 7.0%.
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the study subjects.
In summary, this study demonstrates
that insulin glargine/metformin provides
excellent fasting glycemic control and
that additional exenatide and, to a lesser
degree, sitagliptin, provide additional
postprandial glucose control, without the
necessity for a major change in insulin
dose because of hypoglycemia. In addi-
tion, the weight-reducing ability of ex-
enatide persists despite concomitant
insulin administration. Longer-term
studies are warranted to further explore
the beneﬁts of this novel treatment
approach.
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